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Abstract
Background & Aims: As compared to other chronic diseases, patients with 
chronic liver disease (CLD) have significantly higher inpatient mortality; accurate 
models to predict inpatient mortality are lacking.  Serum lactate (LA) may be 
elevated in patients with CLD due to both tissue hypoperfusion as well as 
decreased lactate clearance.  We hypothesized that a parsimonious model 
consisting of Model for End-stage Liver Disease (MELD) and LA at admission 
may predict inpatient mortality in patients with CLD.  
Approach & Results: We examined all CLD patients in two large and diverse 
healthcare systems in Texas (North Texas, NTX and Central Texas, CTX) 
between 2010-2015. We developed (n=3,588) and validated (n=1,804) a model 
containing MELD and LA measured at time of hospitalization.  We further 
validated the model in a second cohort of 14 tertiary care hepatology centers that 
prospectively enrolled non-elective hospitalized patients with cirrhosis (n=726).  
MELD-LA was an excellent predictor of inpatient mortality in development (c-
statistic =0.81, 95% CI 0.79-0.82) and both validation cohorts (CTX cohort, 
c=0.85, 95% CI 0.78-0.87; multicenter cohort c=0.82, 95% CI 0.74-0.88).  MELD-
LA performed especially well in patients with specific cirrhosis diagnoses (c=0.84, 
95% CI 0.81-0.86) or sepsis (c=0.80, 95% CI 0.78-0.82). For MELD score 25, 
inpatient mortality was 11.2% (LA=1 mmol/L), 19.4% (LA=3 mmol/L), 34.3% 
(LA=5 mmol/L) and >50% (LA >8 mmol/L). A linear increase (p<0.01) was seen 
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improved the risk prediction in 23.5% of the patients as compared to MELD 
model alone.  
Conclusion:  MELD-LA is an early and objective predictor of inpatient mortality 
and may serve as a novel model for risk assessment and guide therapeutic 
options.
Liver disease accounts for approximately 2 million deaths per year worldwide; 
furthermore, chronic liver disease (CLD) related morbidity and mortality is 
underestimated and expected to increase (1). A significant number of encounters 
for patients with CLD occur in the inpatient setting.  As compared to other chronic 
diseases, patients with CLD have significantly higher inpatient mortality; however 
accurate models to predict inpatient mortality are lacking (2).  Model for End-
stage Liver Disease (MELD), the most commonly used predictive model, is an 
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perform well in the inpatient setting (4).  MELD, which comprises of bilirubin, 
international normalized ratio, and creatinine, does not consider other conditions 
that are associated with poor prognosis such as poor tissue perfusion, especially 
in critically ill patients.  Other prognostic scoring systems have been used, either 
based on categorizing the degree of liver disease, (Child-Pugh score (5), or on 
overall clinical severity (APACHE II (6)).  However these other scoring systems 
often are either cumbersome to use, include subjective measures of disease 
severity, are applicable only in the intensive care setting (e.g. APACHE score), or 
may be more reflective of clinical course (e.g. number of organ failures) rather 
than predictive at the time of initial hospitalization (7, 8) .  Simple, objective 
prognostic tools such as neutrophil to lymphocyte ratio have been studied (9) 
however this system lacks specificity to liver disease and may be confounded by 
variables such as nutritional status, type of liver disease (10), and age.  Having 
accurate, early, and objective prediction of mortality with parsimonious variables 
is important for risk assessment, guiding therapeutic options, allocating 
resources, and potentially mitigating premature mortality.
Elevated serum lactate (LA) levels have been associated with poor outcomes 
(11) and may help predict mortality in patients with CLD.  Among patients with 
CLD, LA may be elevated both due to tissue hypoperfusion in the critically ill 
patient as well as decreased lactate clearance in setting of advanced liver and 
renal disease (12).  It may therefore capture an element of disease severity not 
captured by MELD score alone.  Lactate predicts mortality in relevant subsets of 
patients including trauma (13), pneumonia (14), decompensated heart failure 
(15), and gastrointestinal bleeding (16).  Lactate is a predictor of mortality in 
critically ill CLD patients (17) however its role in overall (both ICU and non-ICU) 
CLD patients is unknown.  The addition of lactate to existing prediction models 
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Aims: The primary aim of the study was to develop and validate a parsimonious 
model to predict inpatient mortality in patients with CLD based on objective 
surrogates of disease severity present at admission, namely MELD score and 
serum lactate. 
Setting
Development cohort:  Baylor Scott and White Health (BSWH) is one of the 
largest integrated healthcare systems in the U.S.  Data from patients in North 
Texas division (NTX) region was used for model development while that from 
Central Texas division (CTX) region was used for primary validation. During the 
study period, both these healthcare populations had minimal overlap.   
The North Texas division (NTX) of BSWH serves the Dallas-Fort Worth 
Metroplex and surrounding communities (including 16 hospitals with the 
catchment area of 7 million individuals and over 130,000 annual hospitalizations). 
The Dallas-Fort Worth Metroplex is the largest metropolitan area in Texas and 
the fourth largest metropolitan area (out of 382) in the United States. 
Validation cohort 1:  The central Texas division (CTX) of BSWH serves the 
Austin/Round Rock, Hill Country, College Station, Waco, and Temple regions 
and surrounding communities (including 14 hospitals with the catchment area of 
2.7 million individuals and over 60,000 annual hospitalizations). As compared to 
North Texas, the area encompasses a more rural population and does not have 
direct access to liver transplantation within its region.  
Validation cohort 2: The North American Consortium for the Study of End-
Stage Liver Disease (NACSELD) consists of 14 tertiary care hepatology centers 
in the United States and Canada that prospectively enrolled non-elective 
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Case Ascertainment:  We examined all CLD related hospitalizations from 2010 
to 2015 amongst adult patients (≥18 years) in BSWH system.  Discharge 
diagnoses were classified in accordance with the International Classification of 
Diseases (ICD-9). Based on prior studies, we classified a hospitalization as a 
CLD related hospitalization if it was associated with (a) a primary diagnosis of 
CLD (e.g. cirrhosis) as underlying reason for hospitalization or (b) a secondary 
related complication associated with CLD (e.g. sepsis or hepatic 
encephalopathy) as underlying reason for hospitalization in combination with a 
primary diagnosis of CLD (e.g. alcoholic cirrhosis or viral hepatitis)(2). 
Of all patients with above hospitalizations, we examined all patients that had 
laboratory evaluation to calculate MELD (bilirubin, creatinine, International 
Normalized Ratio) as well as serum lactate measured within 24 hours of 
admission. Similar criteria were applied to the two validation cohorts.
STATISTICAL METHODS
Patients’ characteristics, clinical variables, and outcomes in the development and 
validation cohorts were summarized by mean and standard deviation (or median 
with interquartile range) for continuous variables, and percent or proportion for 
categorical variables. Differences between the two cohorts were assessed by t-
tests or Kruskal-Wallis rank sum tests for continuous variables and chi-square 
test for categorical variables. 
Predictive model building: Using the development dataset, we modeled in-
hospital mortality as dependent variable in a multivariable logistic regression 
model to determine risk factors predictive of mortality. The primary variables of 
interest a priori were MELD score and serum lactate. However, we considered 
other factors that may be associated with inpatient mortality.  Independent 
variables considered in the initial model included: sex, age, race, MELD score  
(21), lactate (11), Charlson’s comorbidity index (22), alcoholic hepatitis (23), 
hepatic encephalopathy (HE) (24), ascites (25), varices (26), malignancy, 
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variable selection algorithm to the initial model and obtained reduced model that 
retained MELD, lactate, age, HE, cirrhosis, and alcoholic hepatitis as significant 
predictors of mortality. We assessed further models with subset of variables from 
the reduced model and evaluated their performance. For each model, we 
obtained Brier scores and c-statistics to compare model prediction accuracy and 
goodness of fit (28-30) We also obtained Akaike Information Criterion (AIC) and 
Bayesian Information Criterion (BIC) to assess the quality of each model relative 
to others and guide in determination of the most parsimonious model (30, 31). 
Supplemental table 1 summarizes prediction accuracy, goodness of fit and 
selection criteria for different models evaluated. The model with MELD and 
lactate provided the best trade-off between goodness of fit, simplicity and 
objective data and was considered for further evaluation. Though age was 
important, it did not markedly improve overall performance (Supplemental 
figure 1). We investigated for interaction between MELD and lactate and found 
no significant statistical interaction.
We observed a nonlinear relationship between the two predictors (MELD and 
lactate) and risk of mortality. Hence, we developed the final model with restrictive 
cubic splines with 4-knots on the continuous predictors to account for nonlinearity 
(32). 
Based on the estimates from the final model, we developed a nomogram with 
point scoring system for ease of application (33, 34). For each predictor, “points” 
were assigned and re-scaled to range from 0 to 25. The points from each 
predictor were then summed to obtain “total points”, which ranged from 0 to 40. 
The total points were used to obtain corresponding probability of death.
Model validation and performance: The new predictive model was validated 
against two independent datasets (CTX and NACSELD). We obtained 
concordance statistics (c-statistics) to quantify the discrimination ability of the 
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predicts a higher probability of having an event among patients who will as 
compared to those that will not have the event. We also obtained Brier score as a 
measure of accuracy of the prediction model. Brier score ranges from 0 to 1, with 
value of 0 implies excellent calibration of the predictive model and 1 implies 
suboptimal calibration (28). The performance of the new model was also 
compared to models that considered MELD alone or lactate alone. We further 
evaluated performance of the final model on subset of patients that included 
alcohol related hepatitis patients only, and patients admitted to ICU. 
 We assessed the calibration to quantify the extent to which absolute risk 
(predicted versus observed) is correctly estimated by a new model (e.g. MELD-
LA) as compared to the old model (MELD).  We calculated the absolute net 
reclassification index (NRI) (35). The absolute NRI calculates the absolute 
number of patients correctly reclassified and consists of the net reclassification of 
patients with the event (correctly identify patients with inpatient mortality) and net 
reclassification of patients without the event (correctly identify patients alive) 
divided by the total number of patients. It ranges from -100% to 100%, and 
represents the percent of patients incorrectly or correctly reclassified. In addition, 
we compared the performance to other competing models that are available at 
the time of admission to include MELD-Na and NLR. 
Data was analyzed using SAS version 9.4 (SAS Institute Inc., Cary, NC) and R 
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Between 2010-2015, there were 14,733 CLD related hospitalizations in the 
development dataset. Of those, 5,614 (38%) patients had a lactate measured on 
admission and 3,588 (24%) had both lactate and parameters for calculating 
MELD. Table 1 summarizes the characteristics of patients in the development 
and primary validation cohorts. The overall mean age was 58.2 years (SD 13.1), 
43% were women, 16.5% were African American and 16.3% were of Hispanic 
ethnicity. The most common cause of hospitalization was sepsis, alcoholic 
cirrhosis and hepatitis C.  The mean MELD score was 18.2 (SD, 8.4) and the 
median lactate was 2.4 mmol/L (IQR 1.5, 3.9).  Overall inpatient mortality was 
17.2%.    
Relation between MELD and lactate
 A nonlinear relationship existed between the two continuous predictors (MELD 
and lactate) and risk of inpatient mortality. The adjusted risk of mortality was 
constant for patients with MELD 6-15, and then increased linearly for those with 
MELD > 15.  Similarly, the adjusted risk of mortality increased linearly with lactate 
levels, but the rate of change was higher for lactate ≤ 10 mmol/L as compared to 
patients with lactate > 10 mmol/L. (Figure 1) 
The impact of lactate varied by severity of liver disease as captured by the MELD 
score (Figure 2). As an example, for a MELD of 15, associated inpatient 
mortality was 15%, 47%, and 62% for lactate 5, 15, and 25 mmol/L, respectively.  
For a MELD of 25, associated inpatient mortality was 32%, 70%, and 81% for 
lactate 5, 15, and 25 mmol/L, respectively.
MELD-LA model
MELD-LA was an excellent predictor of inpatient mortality in development cohort 
(c-statistic =0.81, 95% CI 0.79-0.82) Figure 3 shows the relationship between 
probability of mortality and scores obtained from model developed by MELD and 
lactate (MELD-LA). There was a linear increase in risk of mortality with 
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provided as a nomogram with a point scoring system (Supplemental Figure 2). 
Table 3 summarizes the findings for select cutoffs of MELD and lactate based on 
the MELD-LA score. 
 
Consideration of alternate models
MELD-Na:  The performance of MELD-Na model (c=0.73 95% CI 0.71-0.75) in 
our data was not better than MELD score (c=0.74 95% CI 0.72-0.75).  A model 
combining MELD-Na with lactate (c=0.80, 95% CI 0.78-0.82) did not improve 
performance when compared to MELD-LA model (c = 0.81, 95%CI 0.79-0.83).  
Neutrophil to lymphocyte ratio:  The performance and predictive accuracy of 
neutrophil to lymphocyte ratio was suboptimal (c-statistics = 0.62 and Brier score 
= 0.146).  
We compared MELD-LA at admission to subsequent development of organ
failures over the clinical course. There was a linear increase (p<0.01) in MELD-
LA score with increasing number of organ failures. (Figure 4)
Validation cohort 1, CTX: There were fewer absolute number of 
hospitalizations, however patient demographics were similar between the 
development and validation cohort (Table 1).  Inpatient mortality was significantly 
lower (12.3% vs 19.6%, p<0.001).  The median LA was lower (2.0 mmol/L vs. 2.6 
mmol/L, p=<0.001), and the mean MELD score was lower (16.2 vs. 19.2, 
p=<0.001).  Despite being a less sick cohort, the performance of MELD-LA was 
similarly excellent with a c statistic of 0.85 (95% CI 0.78-0.87). The Brier score 
was also similar between cohorts (0.084) suggesting minimal variation in 
performance between the two datasets. 
Validation cohort 2, NACSELD:  Of 3,057 patients in NACSELD multicenter 
study, 726 subjects met study criteria and had complete data for ascertainment 
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excellent predictor of inpatient mortality (c=0.82, 95% CI 0.74-0.88), similar to the 
current validation group.  Performance for MELD score was c= 0.76 (95% CI 0.67 
- 0.83).
Subsets: We examined the performance within relevant subsets. Performance 
may vary by disease severity. Performance among ICU admissions (c = 0.74 
95% CI 0.72-0.76), those only with alcohol related hepatitis (c=0.77, 95% CI 
0.67-0.88) or a specific cirrhosis diagnosis (c=0.84, 95% CI 0.81-0.86) or sepsis 
(c=0.80, 95% CI 0.78-0.82) was excellent.  Lactate may be influenced by 
presence of patients with cancer. After exclusion, results for MELD-LA still had 
excellent performance (c=0.80, 95% CI 0.78-0.82).  
Calibration: Finally, we examined the absolute net reclassification index to 
quantify differences in observed versus predicted events.  Overall, use of MELD-
LA improved the risk prediction in 23.5% of the patients as compared to MELD 
model alone.  This implies that risk stratification at time of admission by MELD-
LA would have impacted 798 patients during the duration of the study.  Net 
reclassification was higher than incorporation of MELD-Na (+18.2%) or simply 
examination of lactate alone (+5.1%).  The net reclassification of our model as 
compared to NLR was +27%, implying that MELD-LA would have reclassified 
990 patients as compared to NLR.
Discussion:
A disproportionate amount of treatment and care for CLD and cirrhosis is 
provided in the inpatient setting; mortality for CLD remains significant and 
persistently higher than other chronic diseases (2). The MELD score is an 
imperfect predictor of inpatient mortality.  We sought to develop and validate a 
parsimonious and objective model to predict inpatient mortality in patients with 
CLD.  Both MELD score and serum lactate were associated with an increased 
risk of mortality.  MELD-LA assessed at the time of hospitalization was an 
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independent, large, and diverse validation datasets. The independent impact of 
LA varied based on disease severity, as adjudicated by the MELD score.  MELD-
LA model outperformed MELD alone, lactate alone, MELD-Na based models and 
the neutrophil-lymphocyte ratio.  Based on risk reclassification analysis, the 
MELD-LA model improved risk prediction for 23.5% of patients as compared to 
MELD alone.  Clinically, this would have impacted risk prediction for 798 patients 
during the study duration.  Additionally, our study showed that the same lactate 
levels were associated with higher levels of mortality, dependent on the disease 
severity; e.g. a lactate of 3 mmol/L carried a worse prognosis in a patient with a 
MELD of 30 than a MELD of 15.  In addition, MELD-LA correlated with increasing 
number of organ failures. MELD-LA may serve as a putative model for risk 
stratification at the time of hospitalization.
Incorporation of MELD-LA has several advantages.  Addition of LA may capture 
an element of disease severity not entirely encompassed by the MELD score.   It 
is agnostic of subjective factors (ICU care), patient demographics, or underlying 
disease process. It is easily measured at the time of hospitalization and may help 
identify subjects highest at risk prior to identification of triggers. There are several 
potential applications and implications of MELD-LA.  First, it may help stratify 
patients that may need higher levels of care or earlier interventions. Though 
many surrogates of critical illness exist (frailty, ascites, hepatic encephalopathy), 
these may be subjective at the time of presentation and are more reflective of 
current state of health.  With lactate being a predictor of all-cause mortality in 
critically ill patients (37), the inclusion of lactate and its elevation may more 
accurately represent both liver disease and systemic damage occurring in CLD.  
Second, a majority of patients with CLD present with sepsis and septic shock. 
Traditional lactate cutoffs for hospitalized patients without liver disease may not 
apply to chronic liver disease patients (38).  Hence, guidelines for sepsis 
management of critically ill patients for CLD may need further refinement to 
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hospital course may identify patients that are non-responders to therapy. This 
may allow for earlier discussion regarding introduction of palliative care.
Inclusion of LA adds a physiologic explanation for severity of disease and 
increased mortality risk.  Lactate’s prognostic utility has been well established in 
literature (13-16) as well as in selected subsets with cirrhosis (39), however this 
study sheds light on the unique relationship between lactate and all comers with 
liver disease.  Lactic acidosis, a persistent elevation of blood lactate, is most 
commonly related to tissue hypoperfusion and hypoxia (40).  However in chronic 
liver disease patients, the co-presence of lactate elevation not associated with 
hypoperfusion, may be contributing.  The liver is intimately involved in lactate 
clearance, with 40% to 60% being removed by gluconeogenesis (41).  Due to 
impairment in tissue oxygenation and hepatocellular damage in CLD patients, 
gluconeogenesis is impaired, decreasing lactate clearance (41).  In settings that 
may involve hemodynamic permutations (e.g. sepsis), the issue is exacerbated 
and CLD patients may be more prone to lactic acidosis.  Hence, among patients 
with CLD, LA may be elevated both due to tissue hypoperfusion and hypoxia (in 
hepatic and extra hepatic endothelial beds) as well as due to a decreased lactate 
clearance in setting of advanced liver disease (12). 
Our study has several strengths. We were able to capture a broad spectrum of 
patients admitted for complications of CLD in one of the largest metropolitan 
health network.  Additionally, we were able to validate our model and show 
external generalizability in an independent cohort that was more rural and less 
critically ill with minimal overlap between the healthcare systems. We further 
validated our findings in a prospective study of cirrhotics across 14 centers with 
lower inpatient mortality rates.  Referral bias and spectrum bias was minimized 
by considering all hospitalized patients and not simply including tertiary centers 
with liver transplantation. Our study adds to the existing literature looking at the 
role of LA in patients with cirrhosis. Prior studies have explored its role limited to 
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have acute on chronic liver failure (12, 17).  Performance amongst those already 
in the ICU was similar in our study to previous literature. We were able to expand 
and start the measurement from the time of hospitalization regardless of ICU 
status and explored a wider range of LA measurements. We included MELD 
score rather than prior subjective models (5, 17).  We also included serum lactate 
rather than arterial lactate in the expanded cohort. The former is easier to obtain 
and readily available and there appears to be strong correlation between arterial 
and venous lactate (42); however this correlation has not been studied in liver 
patients. In addition, patterns of LA distribution described in the study may have 
implications for management of septic shock in patients with CLD. Consensus 
guidelines suggest a serum lactate level greater than 2 mmol/L after adequate 
fluid resuscitation identifies unselected patients with septic shock (38).  Given the 
higher median LA on admission in patients with CLD, different threshold and 
definitions of response to therapy may be required for this population. 
Our study has limitations. Inpatient mortality rates were high among patients that 
had serum lactate measured.  As expected those that underwent lactate 
measurement were systematically different than those that did not undergo 
measurement.  The mean age of those that did not have measurement was 
slightly younger at 57.2 years (SD 12.7).  Sepsis as a cause for admission was 
significantly lower (44.2% vs. 78.0%) and ICU hospitalization was lower (23% vs 
55%, p<0.01).  Inpatient mortality was also lower at 4.9%.  However, validation in 
two separate cohorts with lower mortality (CTX, 12.3% and NACSELD, 4.8%) 
provides further credence. We were unable to assess whether LA would play a 
role among patients without cause for measurement. This would require 
collection in all patients with CLD that would need to be incorporated at the 
system level.  A future prospective validation is needed whereby lactate is 
measured in all patients with chronic liver disease presenting to the emergency 
room to address this limitation.  The model may overestimate mortality in 
unselected hospitalized patients with CLD.    Use of ICD coding to determine 
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admission.  However, we included a broader definition of CLD to improve case 
ascertainment as previously done (2, 43); the highest accuracy was noted for 
patients with cirrhosis.  
In summary, MELD-LA may serve as a novel parsimonious and objective model 
to identify inpatients with CLD at highest at risk for mortality regardless of ICU 
status. Early prediction may allow for earlier identification of CLD patients that 
may benefit from escalation of care and can also assist in determining starting 
early goal directed therapy.  Alternatively, it may identify patients highest at risk 
for mortality and aid in discussion of prognosis. Further independent validation in 
prospective studies with unbiased lactate measurements and application in 
relevant subsets (e.g. alcohol related hepatitis and risk stratifying patients with 
acute on chronic liver failure), evaluation of change in scores over time and 
comparison to alternate models in the intensive care unit is highly encouraged. 
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Figures
Figure 1a.  Relationship between lactate and log odds of inpatient mortality
Figure 1b.  Relationship between MELD score and log odds of inpatient mortality
Figure 2.  In-hospital mortality by lactate and ranges of MELD values. 
Figure 3.  MELD-Lactate score and probability of inpatient mortality.
Figure 4.  Relationship between derived MELD-LA score and number of organ 
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Table 1: Baseline characteristics of hospitalized patients with measured lactate and 
MELD score at admission in the development (NTX) and validation cohorts (CTX and 
NACSELD). 
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(7.4%) 
 
Charlson’s Index 5.7 (2.9) 5.7 (2.9) 5.6 (3.0) 0.1351 n/a n/a 
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3.4)§ 3.9)§ 2.7)§ 0.0013 5.5)§ 







































18.7 ± 7.3ǂ < 0.0011 
ǂ - mean ± standard deviation; § median (interquartile range); 1 - Student t-test; 2 - 











Table 2. Probability of inpatient mortality by MELD and Lactate Levels based on the 




D 0.5 1 2 3 4 5 6 7 8 10 12 15 20+ 
6 3.6% 3.9% 4.9% 7.2% 10.6% 14.4% 18.2% 21.9% 25.2% 30.8% 35.9% 44.2% 58.5% 
10 3.8% 4.1% 5.2% 7.6% 11.1% 15.1% 19.1% 22.8% 26.3% 32.0% 37.3% 45.6% 59.9% 
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 Lactate 
MEL
D 0.5 1 2 3 4 5 6 7 8 10 12 15 20+ 
20 6.8% 7.4% 9.2% 13.3% 18.9% 24.9% 30.6% 35.6% 39.9% 46.8% 52.6% 61.0% 73.6% 
25 10.3% 11.2% 13.8% 19.4% 26.9% 34.3% 40.9% 46.5% 51.1% 58.0% 63.6% 71.1% 81.4% 
30 14.2% 15.4% 18.7% 25.7% 34.6% 42.9% 49.9% 55.6% 60.1% 66.6% 71.5% 78.0% 86.3% 
35 18.5% 20.0% 24.0% 32.2% 42.1% 50.7% 57.8% 63.2% 67.4% 73.2% 77.5% 83.0% 89.6% 
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